Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05376150 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder
A Phase 2 study, sponsored by Xenon Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 168
- Enrollment target
NCT05376150: Completed Phase 2 study, sponsored by Xenon Pharmaceuticals.
NCT05376150 is a Phase 2 study that has completed, run by Xenon Pharmaceuticals. The registered enrollment target is 168 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (26% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05376150, a Phase 2 study, has completed, sponsored by Xenon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 168 participants
- Enrollment target
Study Summary
This is a multicenter, Phase 2, double-blind, randomized, parallel-arm, placebo-controlled clinical trial to evaluate the efficacy, safety, and tolerability of XEN1101 in subjects with Major Depressive Disorder.
Interventions
- DRUG Placebo
- DRUG XEN1101 10 mg
- DRUG XEN1101 20 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 168 participants |
| Start Date | 2022-05-19 |
| Est. Completion | 2023-10-16 |
| Phase | Phase 2 |
What the finished NCT05376150 record still lists
NCT05376150 is an interventional study that assigns participants to a tested intervention. The registered 168 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (26% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05376150 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05376150 about?
NCT05376150 is a clinical study titled "A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder". This is a multicenter, Phase 2, double-blind, randomized, parallel-arm, placebo-controlled clinical trial to evaluate the efficacy, safety, and tolerability of XEN1101 in subjects with Major Depressive Disorder.
What is the current status of trial NCT05376150?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 168 participants. The study started on 2022-05-19. Estimated completion is 2023-10-16.
What interventions are being tested in trial NCT05376150?
The interventions under investigation include: Placebo (DRUG), XEN1101 10 mg (DRUG), XEN1101 20 mg (DRUG).
Who is sponsoring clinical trial NCT05376150?
This trial is sponsored by Xenon Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05376150's enrollment target sits among peer trials
168 403rd of 2000 higher than 1,595 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02118922 · 168 participants
A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia
- NCT03536897 · 168 participants
IORT Following Breast Conserving Surgery for Early Stage Breast Cancer Registry
- NCT04078230 · 168 participants · NA
Regional or Extend LymphAdenectomy During Resection of Intrahepatic Cholangiocarcinoma
- NCT04159168 · 168 participants · NA
Facial Affect Sensitivity Training for Young Children With Callous-unemotional Traits
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI